Announcements of new AI deals, partnerships and product launches in biopharma are coming at a rapid pace. A new report from Research and Markets, AI In Pharma Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change, predicts this segment will grow from almost $699.3 million in 2020 to more than $2.895 billion in 2025.

Mega-company Johnson & Johnson is planning to break off its consumer products business from J&J’s pharmaceutical and medical device businesses, becoming two publicly traded companies.

POCN, the largest Nurse Practitioner (NP) and Physician Associate (PA) network in the United States, and HealthSTAR Communications, an integrated omni-channel agency network uniquely positioned to deliver cutting-edge proprietary technology and capabilities to healthcare professionals and patients, partnered to bring POCN’s best-in-class Live Local peer-to-peer educational series focused on NPs and PAs.

With more than 1,000 clinical trials for cell and gene therapies in process and predictions that such products will generate $12 billion in revenue annually by 2025, leaders for pharmaceutical companies and health plans must consider how to make gene therapies financially accessible to those who need them. According to Cotiviti Executive Vice President of Operations Jordan Bazinsky, this is an opportunity to explore a new paradigm for reimbursement for complex therapies—one that is informed by collaborative partnership, with careful consideration of the best way to pay for value.

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region’s principal trade association for small to medium-sized companies in the pharmaceutical, biotech and medtech industries.

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

To fast-track the time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies (SUT).

The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030.

Honeycomb Health, a project being created out of Greater Than One’s nonprofit subsidiary GTO Greater Good, was named a finalist in the Top 8 That Innovate. The Top 8 were selected by a panel of pharmaceutical and biotech companies that are members of the Diversity Alliance for Science.

Two very exciting areas where Artificial Intelligence (AI) is having an impact on the life sciences landscape are patient stratification and synthetic control arms. Recent data and technology advances are starting to yield compelling results, according to Derek Baird, President North America of Sensyne Health and Commercial Director of SENSE.